CNBC's Silvia Amaro takes a look at the rise and fall in Novo Nordisk shares.
Breakdown
- Novo Nordisk became Europe's most valuable company after the success of its weight loss drug Wegovy. 19s
- The company issued a profit warning and announced a new CEO, leading to a share price drop. 51s
- Novo Nordisk faces challenges including manufacturing issues, lawsuits, and competition from Eli Lilly. 1m 13s
- Shares rebounded after Eli Lilly's obesity pill showed only modest trial results. 1m 40s
- The CFO stated that raising prices in Europe will be difficult due to public budget pressures. 2m 2s